CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.

Barratt, Daniel T; Cox, Hannah K; Menelaou, Andrew; Yeung, David T; White, Deborah L; Hughes, Timothy P; Somogyi, Andrew A

Barratt, Daniel T; Cox, Hannah K; Menelaou, Andrew; Yeung, David T; White, Deborah L; Hughes, Timothy P; Somogyi, Andrew A.

Affiliation

Barratt DT; Discipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, 5005, Australia. daniel.barratt@adelaide.edu.au.
Cox HK; Centre for Personalised Cancer Medicine, University of Adelaide, Adelaide, SA, Australia. daniel.barratt@adelaide.edu.au.
Menelaou A; Discipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, 5005, Australia.
Yeung DT; South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.
White DL; South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.
Hughes TP; Department of Haematology, SA Pathology, Adelaide, SA, Australia.
Somogyi AA; Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.

Clin Pharmacokinet ; 56(8): 977-985, 2017 08.

Article in En | MEDLINE | ID: mdl-27995529

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Receptor Protein-Tyrosine Kinases / Protein Kinase Inhibitors / Cytochrome P-450 CYP2C8 / Imatinib Mesylate Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Pharmacokinet Year: 2017 Document type: Article Affiliation country: Australia Country of publication: Suiza

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google